期刊文献+

北京市5岁及以上常住人口疫苗接种前新型甲型H1N1流感病毒人群抗体水平分析 被引量:6

Herd immunity against new influenza A(H1N1)in pre-vaccinated residents aged over 5 years in Beijing
原文传递
导出
摘要 目的 了解北京市5岁及以上常住人口接种新型甲型H1N1流感(简称甲型流感)病毒疫苗前的人群抗体水平,为确定防控重点人群提供依据. 方法 2009年10至12月选择未接种疫苗、未明确诊断为甲型流感的北京市常住人口,按照年龄组进行分层,用血凝抑制试验检测新型甲型H1N1流感病毒抗体(简称抗体),使用抗体几何平均滴度进行不同人群的比较. 结果 共监测3499名调查对象,平均抗体水平为1:8.03,阳性率为11.06%(387/3499);5~19岁人群抗体水平和阳性率较高,其抗体水平均〉1:8.9,抗体阳性率均〉12%. 结论 不同人群抗体水平受该人群疫情流行强度的影响,学生人群抗体水平和阳性率高与学校疫情流行强度高有关;北京市采取的重点人群和全人群的免疫策略正确,但目前人群免疫力尚未达到理想状态,甲型流感仍有可能在北京市流行. Objective To explore the herd immunity against influenza A(H1N1)in pre-vaccinated residents aged over 5 years.and therefore to provide data for vaccination policies in high risk populations. Methods From October to December 2009,Beijing CDC conducted a serum survey of the hovel influenza A (H1N1) in the local residents,stratified in 10 age groups between 5 years to over 60 years,without H1N1 vaccination history and disease history.Hemagglutination inhibition (HI) assays were performed at Beijing CDC.Statistical significance was determined with geometric mean titer(GMT). Results 3499 serum samples were tested for HI antibody.The average level of HI antibody was 1:8.03.and 11.06%(387/3499)were sero-positive(HI antibody level≥1:40).In the group aged from 5 to 19 years,the level of HI antibody and the sero-positive rate were higber(HI antibody〉1:8.9.sero-positive rate〉12%). Conclusions The antibody levels in different groups were affected by age specific morbidity,and the higher antibody level of the school-age group was correlated with higher disease intensity in this population.The data showed that the herd immunity in Beijing was under the optimal level,but influenza A(H1N1)would probably become prevalent in the short coming future.
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2010年第6期403-405,共3页 Chinese Journal of Tuberculosis and Respiratory Diseases
关键词 流感病毒A型 H1N1亚型 抗体 病毒 免疫 群体 Influenza A virus, H1N1 subtype Antibodies,viral Immunity, herd
  • 相关文献

参考文献12

  • 1European Committee for Proprietary Medicinal Products.Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96).London:European Agency for the Evaluation of Medicinal Products,1997.
  • 2European Committee for Proprietary Medicinal Products.Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application(CPMP/VEG/4717/03).London:European Agency for the Evaluation of Medicinal Products,2004.
  • 3Fraser C,Donnelly CA,Cauchemez S,et al.Pandemic potential of a strain of influenza A(H1N1):early findings.Science,2009,324:1557-1561.
  • 4蒋贤高,潘景业,施伎蝉,崔小亚,杨守峰,苏菲菲,朱海燕,金方平.甲型H1N1流感临床特征及流行病学分析[J].中华临床感染病杂志,2009,2(4):231-232. 被引量:22
  • 5李亚品,钱全,方立群,杨红,魏茂提,高燕,杨华,张勇,曹务春.中国大陆2009年早期确诊的420例甲型H1N1流感病例流行病学特征分析[J].中华流行病学杂志,2009,30(11):1102-1105. 被引量:39
  • 6Novel Swine-Origin Influenza A(H1N1)Virus Investigation Team,Dawood FS.Jain S,et al.Emergence of a novel swineorigin influenza A(H1N1)virus in humans.N Engl J Med,2009,360:2605-2615.
  • 7Dolin R,Wise TG,Mazur MH,et al.Immunogenicity and reactogenicity of influenza A/New Jersey/76 virus vaccines in normal adults.J Infect Dis.1977,136:S435-S442.
  • 8Cate TR,Kasel JA,Couch RB,et al.Clinical trials of bivalent influenza A/New Jersey/76-A/Victoria/75 vaccines in the elderly.J Infect Dis,1977,136:S518-S525.
  • 9Centers for Disease Control and Prevention(CDC).Serum crossreactive antibody response to a novel influenza A(H1N1) virus after vaccination with seasonal influenza vaccine.MMWR Morb Mortal Wkly Rep,2009,58:521-524.
  • 10Khanna M,Gupta N,Gupta A,et al.Influenza A(H1N1) 2009:a pandemic alarm.J Biosci,2009,34:481-489.

二级参考文献18

  • 1中国卫生部.甲型H1NI流感诊疗方案(试行版).2版.2009.
  • 2http ://www.moh.gov.cn/publicfiles//business/htmlfiles/wsb/index. htm.
  • 3http://www.who.int/csr/disease/swineflu/updates/en/index.html.
  • 4Dawood FS, Seema J, Lyn F, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med, 2009,360 (25) : 2605-2615.
  • 5Human infection with new influenza A (H1N1) virus: clinical observations from a school-associated outbreak in Kobe, Japan, May 2009. Wkly Epidemiol Rec, 2009,84 (24) :237-244.
  • 6Shimada T, Gu Y, Kamiya H, et al. Epidemiology of influenza A (H1N1)virus infection in Japan, May-June 2009. Euro Surveill, 2009,14(24) pii: 19244.
  • 7Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, et al. Epidemiology of new influenza A (H1N1) virus infection, United Kingdom, April-June 2009. Euro Surveill,2009,14(22) : pii: 19232.
  • 8Rizzo C, Declich S, Bella A, et al. Enhanced epidemiological surveillance of influenza A (H1N1) v in Italy. Euro Surveill, 2009,14(27)pii: 19266.
  • 9Khan K, Arino J, Hu W, et al. Spread of a novel influenza A (H1N1) virus via global airline transportation. N Engl J Med, 2009,361(2):212-214.
  • 10中国疾病预防控制中心.http://www.chinacdc.net.cn/n272442/n272530/n3226631/30651.html.

共引文献78

同被引文献62

  • 1邹宇华,陈少贤,周舒冬,邹宗峰,李燕芬,陈思东,陶茂萱,曹兆进,白雪涛,蔡克文,雷春亮.医务人员防护知识和防护意识与SARS感染的关系研究[J].中华医院感染学杂志,2004,14(6):663-665. 被引量:14
  • 2卫生部.甲型H1N1流感诊疗方案(2009年试行版第一版)[EB/OL].http://www.chinac2dc.net.cn/n272442/n272530/n273736/n273781/n4624704/ n4624714/31072, html. 2009.
  • 3卫生部.2009年秋冬季甲型H1N1流感疫苗预防接种指导意见[s].2009-09-10.
  • 4Centers for Disease Control and Prevention. Swine influenza a ( H1N1 ) infection in two children Southern California,March April 2009 [J]. Morb Mortal Wkly Rep, 2009, 58 (15): 400- 402.
  • 5中国疾病预防控制中心.甲型H1N1流感病毒实验室检测技术方案(试行)[S].
  • 6XiaoFeng Liang,HuaQing Wang,JunZhi Wang,et al.Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China:a muhicentre,double-blind,randomised,placebo-controlled trial [ J ].Lancet,2010,375(9708):56-66.
  • 7Van Essen GA,Palache AM,Forleo E,et al.Influenza vaccination in 2000:recommendations and vaccine use in 50 developed and rapidly developing eountries[J].Vaccine, 2003, 21(16): 1780-1785.
  • 8Nolan T,McVernon J,Skeljo M,et al.Immunogenicity of a monovalent 2009 influenza A(H1N1) vaecine in infants and children :a randomized trial [ J ]. JAMA, 2010, 303(1 ): 37-46.
  • 9Plennevaux E,Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA:a preliminary report of two randomized controlled phase 2 trials[J]. Lancet, 2010, 375(9708): 41-48.
  • 10Clark Tw, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvantexl vaccine[J]. N Engl J Med, 2009, 361 (25): 2424-2435.

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部